The T-cell leukemia/lymphoma 1, TCL1, a gene physiologically expressed during T-cell and B-cell development and involved in the pathogenesis of T-cell and B-cell leukemias/ lymphomas, 1 has recently gained novel interest by the discovery that it plays a key regulatory role in the maintenance of the proliferation versus differentiation balance of embryonic stem cells (ES). In ES, in fact, TCL1 is directly activated by Oct3/4 2 and is among the very few genes that are required for the mitotic self-renewal state, and the downregulation of which triggers ES differentiation. 3 The expression of TCL1 was also characterized during preimplantation embryo development, namely in the cells from which ES are derived, where it was found to shuttle between blastomere cortical regions and the nucleus by a cell cycle-dependent fashion and to be required for early blastomere proliferation, but not the acquisition of first embryonal differentiation traits.
4 TCL1 promotes cell proliferation by heterodimerization with AKT/ PKB, a serine/threonine kinase having a central role in the signaling pathways controlling cell proliferation and survival, and mediates both the transphosphorylation of AKT at the Ser472/473 residue 5 and the transfer of phosphorylated AKT to the nucleus. 6 However, it is still unclear if these TCL1 functions are both required for the TCL1-mediated promotion of normal/neoplastic cell growth. We have now addressed this question by studying the preimplantation mouse embryo, a physiological and thoroughly studied system, allowing the intracellular traffic to be analyzed with high spatial and temporal resolution.
We have first determined the state of AKT phosphorylation in early embryos by immunofluorescence analysis, revealing the presence of Ser473-and Thr308-phosphorylated AKT in both one-cell and two-cell embryos (Figure 1a and Supplementary Figure S1 ). Phosphorylated AKT was never localized in pronuclei at the one-cell stage and acquired a prominent nuclear localization in mid two-cell embryos, suggesting that this is the stage at which the AKT-mediated function of TCL1 is first initiated. Therefore, the TCL1 localization in mid onecell embryo pronuclei 4 is independent of AKT. Further study is required to characterize this feature. To study the regulation of AKT phosphorylation during early embryo development, we have probed the functional relevance of kinases known to regulate AKT phosphorylation, including phosphatidylinositol-3-kinase (PI3K) and phosphoinositide-dependent kinase 1 (PDK1), 7 by allowing one-cell embryos to develop in vitro in the continuous presence of kinase inhibitors. Embryo exposure to either 10-20 mM LY294002 or 6-24 nM Wortmannin negatively affected preimplantation development from the four-cell stage (Figure 1b ), in agreement with previous observations. 8 Interestingly, both inhibitors had no apparent effect on the occurrence of the first embryo cleavage, even when the inhibitor concentration in the medium was raised to extremely high values as 100 mM LY294002 or 100 nM Wortmannin (not shown). Embryos exposed to such high inhibitor concentration displayed an altered overall morphology and did not progress beyond the four-cell stage, indicating that the inhibitor had effectively damaged cellular functions (Supplementary Figure S2a) . However, neither LY294002 nor Wortmannin had any effect upon the pattern of Ser473/Thr308 AKT phosphorylation and intracellular distribution at the two-cell stage at all concentrations tested ( Figure 1c and Supplementary Figure S2a) , ruling out the possibility that AKT phosphorylation depended on PI3K and thus on de novo synthesis of PIP 3 at the beginning of embryo development. We then investigated the role of PDK1 on embryonic AKT phosphorylation. In fact, AKT is phosphorylated on Ser473 by the rictor-mTOR complex, whereas PDK1 phosphorylates AKT on Thr308. 9 The PDK1 issue was addressed by culturing embryos in the presence of 10-20 mM of LY333531, a PKCb inhibitor that also inhibits PDK1 in the lower micromolar range. 10 In spite of its negative effect on later preimplantation development, LY333531 did not apparently affect the first embryo cleavage (Figure 1b ) and the AKT phosphorylation pattern of two-cell embryos (Supplementary Figure S2b) . Similar results were also obtained with two-cell embryos that had received an injection of anti-PDK1 antibodies at the one-cell stage (Supplementary Figure  S2c) . We therefore concluded that the phosphorylation state and the intracellular distribution of AKT in two-cell embryos are independent of both PI3K and PDK1 activities, suggesting that AKT is neither de novo Ser473/Thr308-phosphorylated nor dephosphorylated during early stages of preimplantation development. This possibility was tested by determining the total content of phosphorylated AKT in unfertilized eggs and one-cell/two-cell embryos by quantitative immunofluorescence analysis (Figure 1d ). The level of Ser473/Thr308-phosphorylated AKT appeared not to vary significantly across fertilization and the first and second-cell cycles of preimplantation development. In addition, no difference was found between the phosphorylated AKT content of Tcl1 À/À and wildtype two-cell embryos, indicating that TCL1 is not required for Taken together, data obtained with kinase inhibitors and quantitative immunofluorescence analyses support strongly the idea that early mouse embryos inherit fully Ser472/ Thr308-phosphorylated AKT from oogenesis and that initial embryo cleavages are independent on growth factors, making PI3K and PDK1 activities dispensable. This conclusion is in agreement with previous observations that mouse preimplantation embryo development requires PI3K activity from the 8/16-cell stage. 8 If TCL1 is not relevant to AKT phosphorylation in one-cell and two-cell embryos, is this factor needed for the phosphorylated AKT transfer to nucleus? We have addressed this issue by determining the intracellular distribution of Ser473/ Thr308-phosphorylated AKT in two-cell embryos that were genetically deficient in TCL1. Phosphorylated AKT had a striking cortical localization and was lacking in blastomere nuclei (Figure 1e ), pinpointing the cell membrane as an obligatory step among the intracellular movements of phosphorylated AKT. In fact, it is commonly accepted that TCL1 oligomerizes with AKT at the level of cell membrane and that the TCL1-AKT complex is then transferred to nucleus.
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In conclusion, early mouse embryos display a physiological dissociation between the TCL1 functions of AKT phosphorylation and phosphorylated AKT transfer to nucleus, pinpointing the latter function as the essential one for the AKT-mediated promotion of cell proliferation. In addition, the present finding that TCL1 enters one-cell embryo pronuclei, while phosphorylated AKT does not, suggests that TCL1 also plays an AKTindependent role(s) at the beginning of embryo development. In light of the recent finding that TCL1 binds the PNPase exoribonuclease, an enzyme that specifically degrades poly-A þ RNAs, 12 it is tempting to hypothesize that this factor is also relevant for the degradation of maternally derived messages.
